FDA approves labeling changes for ED drugs

Share this article:
The FDA has approved some labeling changes to erectile dysfunction drugs— including Viagra, Cialis, and Levitra—to display more prominently an existing risk on the potential for sudden hearing loss. The changes were also made to Pfizer's Revatio, which contains the same active ingredient (sildenafil) as Viagra.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.